Melanoma-associated antigen 1 peptide–HLA-A*02:01 complex (MAGE-A1/HLA-A*02:01 complex)

The MAGE-A1/HLA-A*02:01 complex is an immune target consisting of a specific antigenic peptide from the cancer-testis antigen MAGE-A1 presented on human MHC class I molecule HLA-A*02:01 at the cell surface. This presentation enables recognition and attack by CD8+ cytotoxic T lymphocytes and is a focus for immune-based therapies against tumors expressing MAGE-A1. Therapeutic approaches include TCR-mimic antibodies and vaccines, which aim to specifically target and eliminate tumor cells displaying the complex, making this entity a crucial focus in the development of targeted cancer immunotherapies.

Other names

MAGEA1/HLA-A*02:01MAGE1/HLA-A*02:01MAGE-A1 peptide–HLA-A*02:01 complexCancer testis antigen/HLA-A*02:01 complexCT1.1/HLA-A*02:01

Immune engagement: Presentation of MAGE-A1 peptides on HLA-A*02:01 leads to recognition and activation of cytotoxic CD8+ T cells or engineered immune effectors (e.g., TCR-mimic antibodies), resulting in tumor cell lysis. Therapeutic antibodies may mimic TCR specificity for the peptide–MHC complex, directing T cell-mediated cytotoxicity against tumor cells presenting the antigen.